|
Gene: E2F3 |
Gene summary for E2F3 |
Gene summary. |
Gene information | Species | Human | Gene symbol | E2F3 | Gene ID | 1871 |
Gene name | E2F transcription factor 3 | |
Gene Alias | E2F-3 | |
Cytomap | 6p22.3 | |
Gene Type | protein-coding | GO ID | GO:0000082 | UniProtAcc | O00716 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1871 | E2F3 | P27T-E | Human | Esophagus | ESCC | 1.78e-10 | 1.44e-01 | 0.1055 |
1871 | E2F3 | P28T-E | Human | Esophagus | ESCC | 1.13e-11 | 2.72e-01 | 0.1149 |
1871 | E2F3 | P30T-E | Human | Esophagus | ESCC | 1.47e-08 | 5.04e-01 | 0.137 |
1871 | E2F3 | P31T-E | Human | Esophagus | ESCC | 9.62e-10 | 1.51e-01 | 0.1251 |
1871 | E2F3 | P32T-E | Human | Esophagus | ESCC | 5.14e-04 | 3.95e-02 | 0.1666 |
1871 | E2F3 | P36T-E | Human | Esophagus | ESCC | 5.87e-04 | 1.52e-01 | 0.1187 |
1871 | E2F3 | P37T-E | Human | Esophagus | ESCC | 2.04e-06 | 1.57e-01 | 0.1371 |
1871 | E2F3 | P39T-E | Human | Esophagus | ESCC | 1.15e-04 | 7.99e-03 | 0.0894 |
1871 | E2F3 | P40T-E | Human | Esophagus | ESCC | 3.95e-02 | 1.76e-01 | 0.109 |
1871 | E2F3 | P42T-E | Human | Esophagus | ESCC | 8.21e-05 | 1.59e-01 | 0.1175 |
1871 | E2F3 | P47T-E | Human | Esophagus | ESCC | 1.52e-11 | 7.43e-02 | 0.1067 |
1871 | E2F3 | P48T-E | Human | Esophagus | ESCC | 1.24e-09 | 8.66e-02 | 0.0959 |
1871 | E2F3 | P52T-E | Human | Esophagus | ESCC | 1.22e-15 | 2.75e-01 | 0.1555 |
1871 | E2F3 | P54T-E | Human | Esophagus | ESCC | 3.20e-07 | 1.08e-01 | 0.0975 |
1871 | E2F3 | P57T-E | Human | Esophagus | ESCC | 3.19e-03 | 5.09e-02 | 0.0926 |
1871 | E2F3 | P61T-E | Human | Esophagus | ESCC | 1.35e-04 | 3.98e-02 | 0.099 |
1871 | E2F3 | P62T-E | Human | Esophagus | ESCC | 2.06e-13 | 1.79e-01 | 0.1302 |
1871 | E2F3 | P65T-E | Human | Esophagus | ESCC | 1.98e-04 | 1.61e-01 | 0.0978 |
1871 | E2F3 | P74T-E | Human | Esophagus | ESCC | 7.35e-06 | 1.63e-01 | 0.1479 |
1871 | E2F3 | P75T-E | Human | Esophagus | ESCC | 1.20e-10 | 1.66e-01 | 0.1125 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00725949 | Cervix | CC | establishment of protein localization to organelle | 99/2311 | 422/18723 | 1.23e-10 | 2.11e-08 | 99 |
GO:00069139 | Cervix | CC | nucleocytoplasmic transport | 71/2311 | 301/18723 | 4.04e-08 | 2.54e-06 | 71 |
GO:00511699 | Cervix | CC | nuclear transport | 71/2311 | 301/18723 | 4.04e-08 | 2.54e-06 | 71 |
GO:00345048 | Cervix | CC | protein localization to nucleus | 68/2311 | 290/18723 | 9.91e-08 | 5.25e-06 | 68 |
GO:00447725 | Cervix | CC | mitotic cell cycle phase transition | 89/2311 | 424/18723 | 2.70e-07 | 1.12e-05 | 89 |
GO:00170388 | Cervix | CC | protein import | 48/2311 | 206/18723 | 8.62e-06 | 1.98e-04 | 48 |
GO:00000824 | Cervix | CC | G1/S transition of mitotic cell cycle | 49/2311 | 214/18723 | 1.16e-05 | 2.48e-04 | 49 |
GO:00448434 | Cervix | CC | cell cycle G1/S phase transition | 53/2311 | 241/18723 | 1.76e-05 | 3.32e-04 | 53 |
GO:00511707 | Cervix | CC | import into nucleus | 38/2311 | 159/18723 | 3.98e-05 | 6.18e-04 | 38 |
GO:00066067 | Cervix | CC | protein import into nucleus | 37/2311 | 155/18723 | 5.13e-05 | 7.71e-04 | 37 |
GO:0072594 | Colorectum | AD | establishment of protein localization to organelle | 148/3918 | 422/18723 | 7.95e-12 | 1.04e-09 | 148 |
GO:0006913 | Colorectum | AD | nucleocytoplasmic transport | 102/3918 | 301/18723 | 1.00e-07 | 4.85e-06 | 102 |
GO:0051169 | Colorectum | AD | nuclear transport | 102/3918 | 301/18723 | 1.00e-07 | 4.85e-06 | 102 |
GO:0034504 | Colorectum | AD | protein localization to nucleus | 94/3918 | 290/18723 | 2.83e-06 | 8.09e-05 | 94 |
GO:0017038 | Colorectum | AD | protein import | 67/3918 | 206/18723 | 6.34e-05 | 1.05e-03 | 67 |
GO:0051170 | Colorectum | AD | import into nucleus | 53/3918 | 159/18723 | 1.76e-04 | 2.38e-03 | 53 |
GO:0006606 | Colorectum | AD | protein import into nucleus | 51/3918 | 155/18723 | 3.29e-04 | 3.86e-03 | 51 |
GO:00725942 | Colorectum | MSS | establishment of protein localization to organelle | 139/3467 | 422/18723 | 5.75e-13 | 1.12e-10 | 139 |
GO:00069132 | Colorectum | MSS | nucleocytoplasmic transport | 99/3467 | 301/18723 | 1.35e-09 | 1.03e-07 | 99 |
GO:00511692 | Colorectum | MSS | nuclear transport | 99/3467 | 301/18723 | 1.35e-09 | 1.03e-07 | 99 |
Page: 1 2 3 4 5 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0516720 | Cervix | CC | Kaposi sarcoma-associated herpesvirus infection | 60/1267 | 194/8465 | 9.74e-09 | 1.58e-07 | 9.33e-08 | 60 |
hsa0516318 | Cervix | CC | Human cytomegalovirus infection | 65/1267 | 225/8465 | 4.59e-08 | 6.47e-07 | 3.83e-07 | 65 |
hsa0421810 | Cervix | CC | Cellular senescence | 49/1267 | 156/8465 | 1.30e-07 | 1.63e-06 | 9.61e-07 | 49 |
hsa0516920 | Cervix | CC | Epstein-Barr virus infection | 57/1267 | 202/8465 | 7.30e-07 | 7.39e-06 | 4.37e-06 | 57 |
hsa0516620 | Cervix | CC | Human T-cell leukemia virus 1 infection | 61/1267 | 222/8465 | 8.13e-07 | 7.98e-06 | 4.72e-06 | 61 |
hsa052226 | Cervix | CC | Small cell lung cancer | 29/1267 | 92/8465 | 4.38e-05 | 3.09e-04 | 1.83e-04 | 29 |
hsa052197 | Cervix | CC | Bladder cancer | 16/1267 | 41/8465 | 1.45e-04 | 9.05e-04 | 5.35e-04 | 16 |
hsa052148 | Cervix | CC | Glioma | 24/1267 | 75/8465 | 1.51e-04 | 9.20e-04 | 5.44e-04 | 24 |
hsa052128 | Cervix | CC | Pancreatic cancer | 24/1267 | 76/8465 | 1.89e-04 | 1.11e-03 | 6.55e-04 | 24 |
hsa015223 | Cervix | CC | Endocrine resistance | 28/1267 | 98/8465 | 3.82e-04 | 1.87e-03 | 1.11e-03 | 28 |
hsa052157 | Cervix | CC | Prostate cancer | 27/1267 | 97/8465 | 7.54e-04 | 3.39e-03 | 2.01e-03 | 27 |
hsa052234 | Cervix | CC | Non-small cell lung cancer | 21/1267 | 72/8465 | 1.48e-03 | 6.32e-03 | 3.74e-03 | 21 |
hsa0522510 | Cervix | CC | Hepatocellular carcinoma | 40/1267 | 168/8465 | 1.52e-03 | 6.39e-03 | 3.78e-03 | 40 |
hsa0522014 | Cervix | CC | Chronic myeloid leukemia | 21/1267 | 76/8465 | 3.08e-03 | 1.19e-02 | 7.03e-03 | 21 |
hsa041106 | Cervix | CC | Cell cycle | 36/1267 | 157/8465 | 4.94e-03 | 1.67e-02 | 9.86e-03 | 36 |
hsa05224 | Cervix | CC | Breast cancer | 32/1267 | 147/8465 | 1.66e-02 | 4.88e-02 | 2.88e-02 | 32 |
hsa05167110 | Cervix | CC | Kaposi sarcoma-associated herpesvirus infection | 60/1267 | 194/8465 | 9.74e-09 | 1.58e-07 | 9.33e-08 | 60 |
hsa0516319 | Cervix | CC | Human cytomegalovirus infection | 65/1267 | 225/8465 | 4.59e-08 | 6.47e-07 | 3.83e-07 | 65 |
hsa0421815 | Cervix | CC | Cellular senescence | 49/1267 | 156/8465 | 1.30e-07 | 1.63e-06 | 9.61e-07 | 49 |
hsa05169110 | Cervix | CC | Epstein-Barr virus infection | 57/1267 | 202/8465 | 7.30e-07 | 7.39e-06 | 4.37e-06 | 57 |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
E2F3 | SNV | Missense_Mutation | novel | c.1178C>A | p.Ser393Tyr | p.S393Y | O00716 | protein_coding | deleterious(0.02) | benign(0.374) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
E2F3 | SNV | Missense_Mutation | c.1391N>A | p.Cys464Tyr | p.C464Y | O00716 | protein_coding | tolerated_low_confidence(0.26) | benign(0.003) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
E2F3 | insertion | In_Frame_Ins | novel | c.693_694insTCCTTTAGTTCATGCATTAGGCAATCCACAAATTGTGTGACACTA | p.Ile231_Lys232insSerPheSerSerCysIleArgGlnSerThrAsnCysValThrLeu | p.I231_K232insSFSSCIRQSTNCVTL | O00716 | protein_coding | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
E2F3 | deletion | Frame_Shift_Del | novel | c.523_524delGA | p.Glu175LysfsTer5 | p.E175Kfs*5 | O00716 | protein_coding | TCGA-AR-A5QQ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD | ||
E2F3 | SNV | Missense_Mutation | novel | c.470G>A | p.Gly157Glu | p.G157E | O00716 | protein_coding | deleterious(0.02) | benign(0.438) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
E2F3 | SNV | Missense_Mutation | c.180C>G | p.Ile60Met | p.I60M | O00716 | protein_coding | tolerated(0.14) | benign(0) | TCGA-C5-A1MJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
E2F3 | SNV | Missense_Mutation | c.473G>A | p.Arg158Lys | p.R158K | O00716 | protein_coding | tolerated(0.35) | benign(0.066) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
E2F3 | SNV | Missense_Mutation | rs765868574 | c.485N>A | p.Arg162Gln | p.R162Q | O00716 | protein_coding | tolerated(0.44) | benign(0.119) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
E2F3 | SNV | Missense_Mutation | c.877N>T | p.Asn293Tyr | p.N293Y | O00716 | protein_coding | deleterious(0) | benign(0.253) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
E2F3 | SNV | Missense_Mutation | novel | c.1103A>T | p.His368Leu | p.H368L | O00716 | protein_coding | tolerated(0.76) | benign(0.027) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |